Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 12 May 21 EFFECT Notice of effectiveness
- 11 May 21 424B3 Prospectus supplement
- 10 May 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 3 May 21 S-4/A Registration of securities issued in business combination transactions (amended)
-
13 Apr 21 S-4 Registration of securities issued in business combination transactions
TPST similar filings
- 10 May 21 Registration of securities issued in business combination transactions (amended)
- 3 May 21 Registration of securities issued in business combination transactions (amended)
- 13 Apr 21 Registration of securities issued in business combination transactions
- 2 Nov 18 Registration of securities issued in business combination transactions (amended)
- 1 Nov 18 Registration of securities issued in business combination transactions (amended)
- 26 Sep 18 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 99.4
CONSENT OF MIKE RAAB
Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, the undersigned hereby consents to be named in the Registration Statement on Form S-4 of Millendo Therapeutics, Inc., a Delaware corporation (the “Company”), and any amendments or supplements thereto, including the prospectus contained therein, as an individual who has agreed to serve as a director of the Company upon completion of the merger, to all references to the undersigned in connection therewith, and to the filing or attachment of this consent as an exhibit to such Registration Statement and any amendment or supplement thereto.
Dated: April 13, 2021
/s/ Mike Raab |
Mike Raab |